Kura Oncology, Inc.

**Signal Note: BVF Partners Initiates $89.5M Position in Kura Oncology** BVF's substantial new stake in KURA likely reflects confidence in the company's pipeline, particularly ziftivamab (anti-DR5 monoclonal antibody) in combination with chemotherapy for ovarian cancer, which is progressing through Phase 2 trials with potential near-term readouts. The concentrated position by a value-focused investor suggests conviction in either near-term clinical catalysts, partnership potential, or valuation arbitrage relative to pipeline de-risking. Key catalyst timing and clinical stage details should be verified against current trial timelines.